358 related articles for article (PubMed ID: 32061374)
21. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study.
Gutiérrez-Gutiérrez B; Salamanca E; de Cueto M; Hsueh PR; Viale P; Paño-Pardo JR; Venditti M; Tumbarello M; Daikos G; Cantón R; Doi Y; Tuon FF; Karaiskos I; Pérez-Nadales E; Schwaber MJ; Azap ÖK; Souli M; Roilides E; Pournaras S; Akova M; Pérez F; Bermejo J; Oliver A; Almela M; Lowman W; Almirante B; Bonomo RA; Carmeli Y; Paterson DL; Pascual A; Rodríguez-Baño J;
Lancet Infect Dis; 2017 Jul; 17(7):726-734. PubMed ID: 28442293
[TBL] [Abstract][Full Text] [Related]
22. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections.
Daikos GL; Petrikkos P; Psichogiou M; Kosmidis C; Vryonis E; Skoutelis A; Georgousi K; Tzouvelekis LS; Tassios PT; Bamia C; Petrikkos G
Antimicrob Agents Chemother; 2009 May; 53(5):1868-73. PubMed ID: 19223638
[TBL] [Abstract][Full Text] [Related]
23. Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae.
Cprek JB; Gallagher JC
Antimicrob Agents Chemother; 2016 Jan; 60(1):669-73. PubMed ID: 26552970
[TBL] [Abstract][Full Text] [Related]
24. Mortality-related factors in patients with OXA-48 carbapenemase-producing Klebsiella pneumoniae bacteremia.
Rodríguez OL; Sousa A; Pérez-Rodríguez MT; Martínez-Lamas L; Suárez RL; Martínez CT; Pino CP; Vidal FV; Pérez-Landeiro A; Casal MC
Medicine (Baltimore); 2021 Apr; 100(14):e24880. PubMed ID: 33832068
[TBL] [Abstract][Full Text] [Related]
25. Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia.
Seo H; Lee SC; Chung H; Ra SH; Sung H; Kim MN; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Woo JH; Chong YP
Int J Antimicrob Agents; 2020 Oct; 56(4):106126. PubMed ID: 32755654
[TBL] [Abstract][Full Text] [Related]
26. Risk Factors for Carbapenem-resistant
Wang Z; Qin RR; Huang L; Sun LY
Chin Med J (Engl); 2018 Jan; 131(1):56-62. PubMed ID: 29271381
[TBL] [Abstract][Full Text] [Related]
27. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.
Qureshi ZA; Paterson DL; Potoski BA; Kilayko MC; Sandovsky G; Sordillo E; Polsky B; Adams-Haduch JM; Doi Y
Antimicrob Agents Chemother; 2012 Apr; 56(4):2108-13. PubMed ID: 22252816
[TBL] [Abstract][Full Text] [Related]
28. Risk factors and mortality for patients with Bloodstream infections of Klebsiella pneumoniae during 2014-2018: Clinical impact of carbapenem resistance in a large tertiary hospital of China.
Chang H; Wei J; Zhou W; Yan X; Cao X; Zuo L; Chen S; Yao K; Huang R; Chen Y; Wu C
J Infect Public Health; 2020 May; 13(5):784-790. PubMed ID: 31843651
[TBL] [Abstract][Full Text] [Related]
29. A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting.
Aslan AT; Kırbaş E; Sancak B; Tanrıverdi ES; Otlu B; Gürsoy NC; Yılmaz YA; Tozluyurt A; Liste Ü; Bıçakcıgil A; Hazırolan G; Dağ O; Güven GS; Akova M;
Int J Antimicrob Agents; 2022 Apr; 59(4):106554. PubMed ID: 35176476
[TBL] [Abstract][Full Text] [Related]
30. Clinical features of patients with carbapenem nonsusceptible Klebsiella pneumoniae and Escherichia coli in intensive care units: a nationwide multicenter study in Taiwan.
Chang YY; Chuang YC; Siu LK; Wu TL; Lin JC; Lu PL; Wang JT; Wang LS; Lin YT; Huang LJ; Fung CP
J Microbiol Immunol Infect; 2015 Apr; 48(2):219-25. PubMed ID: 25074627
[TBL] [Abstract][Full Text] [Related]
31. Triple combination antibiotic therapy for carbapenemase-producing Klebsiella pneumoniae: a systematic review.
Jacobs DM; Safir MC; Huang D; Minhaj F; Parker A; Rao GG
Ann Clin Microbiol Antimicrob; 2017 Nov; 16(1):76. PubMed ID: 29178957
[TBL] [Abstract][Full Text] [Related]
32. Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant Klebsiella pneumoniae bloodstream infections.
Oliva A; D'Abramo A; D'Agostino C; Iannetta M; Mascellino MT; Gallinelli C; Mastroianni CM; Vullo V
J Antimicrob Chemother; 2014 Jun; 69(6):1718-20. PubMed ID: 24521856
[No Abstract] [Full Text] [Related]
33. Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.
Shields RK; Nguyen MH; Chen L; Press EG; Potoski BA; Marini RV; Doi Y; Kreiswirth BN; Clancy CJ
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559250
[TBL] [Abstract][Full Text] [Related]
34. Carbapenem Resistance, Initial Antibiotic Therapy, and Mortality in Klebsiella pneumoniae Bacteremia: A Systematic Review and Meta-Analysis.
Kohler PP; Volling C; Green K; Uleryk EM; Shah PS; McGeer A
Infect Control Hosp Epidemiol; 2017 Nov; 38(11):1319-1328. PubMed ID: 28950924
[TBL] [Abstract][Full Text] [Related]
35. External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant Klebsiella pneumoniae bacteraemia cohort: the prognostic significance of colistin resistance.
Machuca I; Gutiérrez-Gutiérrez B; Rivera-Espinar F; Cano A; Gracia-Ahufinger I; Guzman-Puche J; Marfil-Pérez E; Pérez-Nadales E; Castón JJ; Bonomo RA; Carmeli Y; Paterson D; Pascual Á; Martínez-Martínez L; Rodríguez-Baño J; Torre-Cisneros J;
Int J Antimicrob Agents; 2019 Oct; 54(4):442-448. PubMed ID: 31377343
[TBL] [Abstract][Full Text] [Related]
36. Bloodstream Infections due to Carbapenem-Resistant
Shen L; Lian C; Zhu B; Yao Y; Yang Q; Zhou J; Zhou H
Microb Drug Resist; 2021 Feb; 27(2):227-233. PubMed ID: 32584202
[TBL] [Abstract][Full Text] [Related]
37. Carbapenem resistant Klebsiella pneumoniae isolated from bloodstream infection: Indian experience.
Veeraraghavan B; Shankar C; Karunasree S; Kumari S; Ravi R; Ralph R
Pathog Glob Health; 2017 Jul; 111(5):240-246. PubMed ID: 28670975
[TBL] [Abstract][Full Text] [Related]
38. High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A retrospective cohort study.
Geng TT; Xu X; Huang M
Medicine (Baltimore); 2018 Feb; 97(8):e9961. PubMed ID: 29465589
[TBL] [Abstract][Full Text] [Related]
39. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes.
Nguyen M; Eschenauer GA; Bryan M; O'Neil K; Furuya EY; Della-Latta P; Kubin CJ
Diagn Microbiol Infect Dis; 2010 Jun; 67(2):180-4. PubMed ID: 20356699
[TBL] [Abstract][Full Text] [Related]
40. The effect of colistin resistance and other predictors on fatality among patients with bloodstream infections due to Klebsiella pneumoniae in an OXA-48 dominant region.
Menekşe Ş; Çağ Y; Işık ME; Şahin S; Hacıseyitoğlu D; Can F; Ergonul O
Int J Infect Dis; 2019 Sep; 86():208-211. PubMed ID: 31402295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
